Medy-Tox Inc. (KOSDAQ:086900)
South Korea · Delayed Price · Currency is KRW 67,300
-800 (-1.17%)
Sep 22, 2026, 3:30 PM KST
Medy-Tox Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 439,807 | 847,985 | 831,097 | 1,621,720 | 806,183 | 876,202 | |
Market Cap Growth | -51.05% | 2.03% | -48.75% | 101.16% | -7.99% | -13.91% |
Enterprise Value | 521,360 | 867,873 | 890,261 | 1,671,460 | 885,688 | 929,154 |
Last Close Price | 68100.00 | 120800.00 | 123558.21 | 237269.69 | 125467.58 | 133151.58 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 30.43 | 54.29 | 52.01 | 184.70 | 22.37 | 9.40 |
Forward PE | 15.63 | 35.44 | 19.78 | 31.76 | 27.88 | 23.25 |
PS Ratio | 1.75 | 3.43 | 3.64 | 7.33 | 4.13 | 4.74 |
PB Ratio | 1.16 | 1.87 | 1.74 | 3.42 | 1.86 | 2.17 |
P/TBV Ratio | 1.19 | 1.90 | 1.84 | 3.49 | 1.90 | 2.23 |
P/FCF Ratio | 8.09 | 18.54 | 29.86 | 276.65 | 49.45 | 357.35 |
P/OCF Ratio | 6.43 | 13.81 | 22.74 | 119.94 | 30.77 | 43.89 |
PEG Ratio | - | 1.40 | 1.40 | 1.40 | 1.40 | 1.40 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.08 | 3.51 | 3.89 | 7.56 | 4.54 | 5.03 |
EV/EBITDA Ratio | 17.29 | 23.62 | 22.09 | 51.12 | 14.34 | 18.08 |
EV/EBIT Ratio | 51.93 | 52.04 | 43.75 | 96.49 | 18.98 | 28.04 |
EV/FCF Ratio | 9.58 | 18.97 | 31.99 | 285.14 | 54.32 | 378.95 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.33 | 0.17 | 0.17 | 0.18 | 0.28 | 0.33 |
Debt / EBITDA Ratio | 3.36 | 2.09 | 2.02 | 2.53 | 1.96 | 2.59 |
Debt / FCF Ratio | 2.29 | 1.68 | 2.92 | 14.13 | 7.41 | 54.21 |
Net Debt / Equity Ratio | 0.20 | 0.06 | 0.05 | 0.10 | 0.22 | 0.13 |
Net Debt / EBITDA Ratio | 2.06 | 0.75 | 0.54 | 1.51 | 1.53 | 0.99 |
Net Debt / FCF Ratio | 1.41 | 0.61 | 0.78 | 8.44 | 5.81 | 20.80 |
Asset Turnover | 0.44 | 0.41 | 0.37 | 0.37 | 0.33 | 0.35 |
Inventory Turnover | 2.17 | 1.95 | 1.45 | 1.56 | 1.61 | 2.25 |
Quick Ratio | 0.74 | 1.02 | 1.04 | 0.79 | 0.57 | 1.14 |
Current Ratio | 1.03 | 1.48 | 1.67 | 1.31 | 1.00 | 1.49 |
Return on Equity (ROE) | 3.59% | 3.36% | 3.38% | 2.13% | 8.74% | 28.77% |
Return on Assets (ROA) | 1.85% | 1.74% | 2.07% | 1.79% | 4.97% | 3.96% |
Return on Invested Capital (ROIC) | 3.71% | 3.40% | 3.66% | 2.01% | 7.02% | 6.09% |
Return on Capital Employed (ROCE) | 4.10% | 3.50% | 4.00% | 3.60% | 10.10% | 7.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.26% | 1.96% | 2.04% | 0.60% | 4.59% | 10.75% |
FCF Yield | 12.37% | 5.39% | 3.35% | 0.36% | 2.02% | 0.28% |
Dividend Yield | 1.78% | 0.99% | - | - | - | - |
Payout Ratio | 58.22% | 53.75% | 49.69% | 86.33% | 21.74% | - |
Buyback Yield / Dilution | 0.03% | 2.03% | -0.40% | -2.02% | -2.28% | -0.04% |
Total Shareholder Return | 1.80% | 3.02% | -0.40% | -2.02% | -2.28% | -0.04% |